Phaseline

Targets › EPAS1

EPAS1 (Endothelial PAS domain-containing protein 1): drug programs, companies and trials

2 programs from 2 companies in 26 trials: 11 Phase 2, 8 Phase 3, 6 Phase 1, 1 Phase 4; Oncology; next expected readout Nov 2026.

Transcription factor involved in the induction of oxygen regulated genes. Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters (By similarity). (UniProt, Q99814)

Open in Phaseline: the race on EPAS1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Merck & Co. (MSD)Belzutifan (MK-6482)
Endothelial PAS domain-containing protein 1 inhibitor
EPAS1Phase 3Carcinoma, Renal Cell; Renal Cell Carcinoma; Von Hippel-Lindau Disease; Neoplasm Malignant …Dec 2026
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Belzutifan (PT2977)
Endothelial PAS domain-containing protein 1 inhibitor
EPAS1Phase 2Renal Cell Carcinoma (RCC); VHL - Von Hippel-Lindau Syndrome; Advanced Solid Tumors; ccRCCNov 2026

Conditions

Carcinoma, Renal Cell (6) Renal Cell Carcinoma (4) Pheochromocytoma and Paraganglioma (PPGL) (2) Von Hippel-Lindau Disease (1) Neoplasm Malignant (1) Metastatic Breast Cancer (1) Pheochromocytoma/Paraganglioma (1) Malignant Neoplasm (1) Metastatic Castration-Resistant Prostate Cancer (1) Ovarian Cancer (1) Clear Cell Renal Cell Carcinoma (1) Active Surveillance (1)

Modalities

small molecule (2)

Companies

Merck & Co. (MSD) (1) Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.